Deep Tech

The Startups Building the Machines That Could Work the Moon

Getting to the Moon was the first chapter. Interlune and Astrolab are working on how to operate there.

Updated

March 6, 2026 1:32 AM

Apollo 17 Astronaut's Snapshot of Taurus-Littrow Valley. PHOTO: UNSPLASH

As plans for a long-term human presence on the Moon pick up pace, the focus is shifting from landing there to working there. It is one thing to reach the surface. It is another to build roads, prepare sites and extract materials in a way that can support real activity.

That is where Interlune and Astrolab come in. Interlune is a space resources company. Astrolab builds planetary rovers. The two are now working together to mount Interlune’s lunar digging system onto Astrolab’s Flexible Logistics and Exploration (FLEX) rover. They have completed a concept study and are planning hardware testing in Houston.

The aim is straightforward: combine a rover that can move reliably across the Moon with equipment that can dig, collect and handle lunar soil. Interlune is focused on harvesting natural resources from the Moon, starting with helium-3. To do that at scale, the system cannot sit in one place. It has to move across the surface, handle dust and operate in harsh conditions. "Reliable, autonomous mobility is crucial to the Interlune harvesting system and broader lunar infrastructure development", said Rob Meyerson, co-founder and CEO of Interlune. "Astrolab's FLEX is the right vehicle for the job".

By fitting its digging and collection hardware onto FLEX, Interlune is working toward a mobile system that can gather large amounts of lunar soil and support future construction needs. Beyond helium-3, the same setup could help prepare base sites, level ground, build protective barriers and lay the groundwork for other structures. In simple terms, it is about turning a rover into a working machine for the Moon.

The partnership also connects to Interlune’s work with Vermeer Corporation to develop equipment for continuous, high-volume digging adapted to lunar conditions. Taken together, the goal is to build systems that can support both commercial and government missions — whether that means resource extraction or preparing land for future bases.

For Astrolab, the collaboration strengthens the role of FLEX as more than just a transport vehicle.

"Working with Interlune further differentiates FLEX as the rover of choice for commercial and government Moon missions", said Jaret Matthews, Astrolab founder and CEO. "Interlune's expertise in developing and testing highly specialized regolith simulant will further enhance FLEX's ability to mitigate dust and operate in extreme environments".

Testing will be centered in Houston, which is becoming an important hub for commercial space development. Astrolab was the first company to lease space at the Texas A&M University Space Institute, currently under construction at NASA’s Johnson Space Center. Interlune operates the Houston-based Interlune Research Lab, where it creates and tests simulated versions of lunar soil.

That detail matters. Moon dust is fine, abrasive and difficult to manage. Before any hardware flies, it needs to prove it can survive and function in those conditions. By testing their systems in realistic soil simulants, the companies can refine how the rover moves and how the digging system performs.

The Houston lab is partially funded by the Texas Space Commission, reflecting the growing role of regional space initiatives in supporting private companies building beyond Earth. Overall, the collaboration is not about grand promises. It is about integrating hardware, running real tests and taking practical steps toward operating on the Moon.  

Keep Reading

Health & Biotech

OpenAI and Top Investors Back Valthos with US$30M to Advance AI-Driven Biodefense

Reimagining biodefense at the intersection of AI, biology and urgency.

Updated

January 8, 2026 6:34 PM

Through computational tools, Valthos analyzes biological data to design adaptive solutions against emerging threats. PHOTO: VALTHOS

Valthos has raised US$30 million in seed funding, led by the OpenAI Startup Fund, Lux Capital and Founders Fund, to advance its mission of building next-generation biodefense systems.

The company’s work comes at a time when biotechnology is evolving at an unprecedented pace. Biotechnology is moving at record speed. These new tools can lead to life-changing medical discoveries, but they also bring the risk of dangerous biological agents being developed faster than ever.  

“The issue at the core of biodefense is asymmetry”, said Kathleen McMahon, co-founder of Valthos. “It’s easier to make a pathogen than a cure. We’re building tools to help experts at the frontlines of biodefense move as fast as the threats they face”. The gap Valthos aims to close is between the rapid rise of biological threats and the slower pace of developing cures. Therefore, the company is developing AI systems that can rapidly analyze biological sequences and significantly shorten the time needed to design medical countermeasures.

“In this new world, the only way forward is to be faster. So we set out to build a new tech stack for biodefense”, said Tess van Stekelenburg, co-founder of Valthos. “This software infrastructure strengthens biodefense today and lays the groundwork for the adaptive, precision therapeutics of tomorrow”.

The company was founded by van Stekelenburg, a partner at Lux Capital and McMahon, the former head of Palantir’s Life Sciences division. Together, they’ve built a multidisciplinary team of experts from Palantir, DeepMind, Stanford’s Arc Institute and MIT’s Broad Institute, bringing together deep experience in software engineering, machine learning and biotechnology.

“Technology is moving fast. An industrial ecosystem of builders, companies and solutions further democratizes AI to provide broad resilience, and ensures the U.S. continues to lead as AI increasingly powers everything around us. As AI and biotech rapidly advance, biodefense is one of the new industry verticals that helps maximize the benefits and minimize the risks”, said Jason Kwon, OpenAI’s Chief Strategy Officer. “Valthos is pushing the frontier of protection and defense in one of the most strategic intersections of multiple world-changing technologies, and with the team to do it”.

Looking ahead, Valthos plans to expand its engineering team and scale its software infrastructure for both government and commercial partners — moving closer to its goal of enabling faster, smarter and more adaptive biodefense capabilities.